NeuroSense Therapeutics Ltd.

NasdaqCM NRSN

NeuroSense Therapeutics Ltd. Revenue for the year ending December 31, 2023: USD 0.00

NeuroSense Therapeutics Ltd. Revenue is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

NeuroSense Therapeutics Ltd. Revenue for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
NeuroSense Therapeutics Ltd. Revenue for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
NeuroSense Therapeutics Ltd. Revenue for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
NeuroSense Therapeutics Ltd. Revenue for the year ending December 31, 2019 was USD 0.00.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: NRSN

NeuroSense Therapeutics Ltd.

CEO	Mr. Alon Ben-Noon
IPO Date	Dec. 9, 2021
Location	Israel
Headquarters	Building B
Employees	18
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Key trends

Past 5 years